DIAL Health Supplement

项目摘要 卡路里限制（CR）的定义是吃营养充足的饮食，低于能量需求。CR 已经被研究了近100年，并已被发现延长寿命和健康的许多 物种此外，当在年轻人和中年人中进行测试时，适度的CR可以改善健康寿命， 生物老化然而，已发现对CR的依从性随着时间的推移而降低，这引起了人们对 这种方法的长期可行性。CR的可能替代方案，可能具有更好的依从性， 可接受的是时间限制饮食（TRE），这涉及在8到10小时内吃一个人的食物。 天TRE延长了啮齿动物的寿命，根据最近的人体试验，TRE改善了疾病风险 老化的因素和生物标志物。此外，TRE的许多益处即使在体重减轻不 发生.虽然CR和TRE的几个健康益处已经被记录在案，但这些益处的影响仍然存在。 干预措施，即TRE，对癌症风险的影响尚不清楚。因此，拟议的行政补充将 支持分析旨在解决与时间限制饮食（TRE）和CR相关的未回答问题 和癌症风险。该补充将支持奖励U 01 AG 073204（拨号健康，一个规划项目，以试点 测试和优化饮食方法以减缓衰老并设计长期试验）和U 01 AG 073240（HALLO- P，健康老龄化和晚年结局规划），以收集癌症相关终点，包括癌症史 和筛选，扩大炎症生物标志物评估和肠道微生物组。两个家长奖 是临床试验，测试CR和TRE对衰老生物标志物的影响。具体来说，在Dial 健康研究，这是在彭宁顿生物医学（巴吞鲁日，洛杉矶）和 亚拉巴马在伯明翰（伯明翰，AL），数据将收集90名成年人谁是参与 一项为期6个月的随机对照试验。在维克森林进行的HALLO-P研究期间 大学健康科学（北卡罗来纳州温斯顿-塞勒姆），将招募120名老年人参加为期9个月的随机研究 对照试验

Project Summary Calorie restriction (CR) is defined as eating a nutritionally adequate diet that is below energy requirements. CR has been studied for almost 100 years and has been found to extend the lifespan and healthspan of numerous species. Further, when tested in young and middle-aged humans, modest CR improves healthspan and slows biological aging. However, adherence to CR has been found to decrease over time, calling into question the long-term viability of this approach. A possible alternative to CR that may have better adherence and acceptability is time-restricted eating (TRE), which involves eating one's food in an 8 to 10-hour period of the day. TRE extends the lifespan of rodents, and based on recent human trials, TRE improved disease risk factors and biomarkers of aging. Further, many benefits of TRE were achieved even when weight loss did not occur. Although several health benefits of CR and TRE have been documented, the effect of these interventions, namely TRE, on cancer risk is unclear. Thus, the proposed administrative supplement will support analyses aimed at addressing unanswered questions related to time-restricted eating (TRE) and CR and cancer risk. The supplement will support awards U01 AG073204 (DiAL Health, A planning project to pilot test and optimize dietary approaches to slow aging and design a long-term trial) and U01 AG073240 (HALLO- P, Health Aging & Later-Life Outcomes Planning) to collect cancer-related endpoints, including cancer history and screening, an expanded inflammatory biomarker assessment, and gut microbiome. The two parent awards are clinical trials that are testing the effects of CR and TRE on aging biomarkers. Specifically, in the DiAL Health study, which is being conducted at Pennington Biomedical (Baton Rouge, LA) and the University of Alabama at Birmingham (Birmingham, AL), data will be collected from 90 adult individuals who are participating in a 6-month randomized controlled trial. During the HALLO-P study, which is being conducted at Wake Forest University Health Sciences (Winston-Salem, NC), 120 older adults will be enrolled in a 9-month randomized controlled trial.